Avadel Pharmaceuticals PLC
$ 21.59
0.05%
26 Dec - close price
- Market Cap 2,118,867,000 USD
- Current Price $ 21.59
- High / Low $ 21.60 / 21.51
- Stock P/E N/A
- Book Value 1.01
- EPS N/A
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE N/A %
- 52 Week High 23.57
- 52 Week Low 6.38
About
Avadel Pharmaceuticals PLC is a biopharmaceutical company based in Dublin, focused on developing innovative therapies for rare and complex medical conditions, particularly in sleep medicine and endocrine disorders. With a robust product pipeline and specialized expertise in drug formulation and delivery, Avadel addresses significant unmet medical needs, positioning itself for substantial growth. The company is actively pursuing strategic partnerships to broaden its market presence and expedite product development, ultimately aiming to improve patient outcomes in critical therapeutic areas.
Analyst Target Price
$20.94
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-07 | 2025-05-06 | 2025-03-03 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-09 | 2023-05-04 | 2023-03-29 |
| Reported EPS | 0.0002 | 0.1 | -0.05 | -0.05 | -0.0273 | -0.14 | -0.3 | -0.29 | -0.41 | -0.83 | -0.48 | -0.46 |
| Estimated EPS | 0.07 | 0.03 | -0.07 | -0.02 | -0.05 | -0.16 | -0.21 | -0.26 | -0.37 | -0.38 | -0.38 | -0.27 |
| Surprise | -0.0698 | 0.07 | 0.02 | -0.03 | 0.0227 | 0.02 | -0.09 | -0.03 | -0.04 | -0.45 | -0.1 | -0.19 |
| Surprise Percentage | -99.7143% | 233.3333% | 28.5714% | -150% | 45.4% | 12.5% | -42.8571% | -11.5385% | -10.8108% | -118.4211% | -26.3158% | -70.3704% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.0948 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVDL
2025-12-24 15:10:21
Investment firm Janus Henderson Group plc has disclosed a 1.89% stake in Avadel Pharmaceuticals plc, as reported in a regulatory filing. The disclosure, made under Irish Takeover Panel rules, indicates Janus Henderson holds 1,841,186 ordinary shares, with a small portion not subject to their voting discretion. Avadel Pharmaceuticals focuses on central nervous system disorders and trades on Nasdaq.
2025-12-24 07:24:00
Janus Henderson Group plc has disclosed a 1.89% stake in Avadel Pharmaceuticals plc, as reported in a regulatory filing. This disclosure, made under Irish Takeover Panel rules, indicates that Janus Henderson holds 1,841,186 ordinary shares in Avadel as of December 23, 2025. The filing also noted a small transaction involving the purchase of 16 Avadel ordinary shares and clarified that Janus Henderson does not have voting discretion for a portion of these shares.
2025-12-23 16:09:31
BlackRock, Inc. has announced a 6.92% ownership stake in Avadel Pharmaceuticals plc, as revealed in a recent regulatory filing. The investment management firm holds 6,797,176 ordinary shares of Avadel, with minimal short positions. This disclosure was made under Irish Takeover Panel rules following BlackRock's trading activity on December 22.
2025-12-23 16:09:31
Citadel Group has disclosed a 1.09% stake in Avadel Pharmaceuticals plc, as revealed in a regulatory filing. This position includes both owned shares and stock-settled derivatives, alongside short positions. The disclosure was made under Irish Takeover Panel rules, which require reporting when an entity holds 1% or more of a company's securities.
2025-12-23 15:09:31
Geode Capital Management has disclosed a 2.2% ownership stake in Avadel Pharmaceuticals plc (NASDAQ:AVDL) through a regulatory filing. The firm holds 2,162,788 ordinary shares in the Irish pharmaceutical company and recently sold 6,475 shares. This disclosure adheres to Irish Takeover Panel Act requirements for significant shareholders.
2025-12-22 15:09:29
Citadel Group has disclosed a 1.11% stake in Avadel Pharmaceuticals plc, as revealed in a recent regulatory filing under Irish Takeover Panel rules. The investment firm holds 1,096,096 shares in the Dublin-based pharmaceutical company as of December 19, 2025, through a combination of owned shares, controlled shares, and stock-settled derivatives. Citadel also reported short positions equivalent to 0.97% of Avadel’s shares, and the filing detailed various transactions including purchases, sales, and call option exercises by the firm.
